• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[基于外照射剂量的接受治疗剂量131I患者出院回家及返回普通病房的标准]

[Levels for discharge to home and return to general ward of patients who received therapeutic dose of 131I based on external exposure dose].

作者信息

Koshida K, Koga S, Orito T, Hiraki T, Takeuchi A, Nishizawa K, Ito K

出版信息

Kaku Igaku. 1989 May;26(5):591-9.

PMID:2607683
Abstract

This paper describes levels for discharge from hospital and return to general ward of patients treated with 131I. The level was determined by comparing the possible exposure dose to those individuals whom the patients are in daily contact with the annual dose limit for the public. The external exposure dose was calculated by using the data on the distance between the patient and individuals, length of the time spent at each distance, and each individual's age. The following levels were obtained: (1) For the patient to be discharged from the hospital, the maximum residual radioactivity should be less than 0.51 GBq if the distance from the patient in bedroom is 50 cm or more and the ages of her children are all over one year. No restriction is needed for the patient with residual radioactivity of 0.20 GBq. (2) For the patient to be returned to the general ward, the maximum residual radioactivities should be 28 MBq and 41 MBq, corresponding to the distance from the patient of 2.0 m and 2.5 m respectively. We established a method to analyze the factors affecting the level.

摘要

本文描述了接受¹³¹I治疗的患者出院及返回普通病房的标准。该标准是通过将患者可能对与其日常接触的人员造成的照射剂量与公众年剂量限值进行比较来确定的。利用患者与他人之间的距离、在每个距离处停留的时间长度以及每个人的年龄等数据计算外照射剂量。得出以下标准:(1)对于即将出院的患者,如果其在卧室中与他人的距离为50厘米或更远且其子女年龄均超过一岁,则最大残留放射性应小于0.51吉贝可。残留放射性为0.20吉贝可的患者无需限制。(2)对于即将返回普通病房的患者,最大残留放射性分别应为28兆贝可和41兆贝可,对应患者与他人的距离分别为2.0米和2.5米。我们建立了一种分析影响该标准的因素的方法。

相似文献

1
[Levels for discharge to home and return to general ward of patients who received therapeutic dose of 131I based on external exposure dose].[基于外照射剂量的接受治疗剂量131I患者出院回家及返回普通病房的标准]
Kaku Igaku. 1989 May;26(5):591-9.
2
[A study on the isolation period of patients with metastatic thyroid cancer treated by 131I according to a new guideline].[一项依据新指南对接受¹³¹I治疗的转移性甲状腺癌患者隔离期的研究]
Kaku Igaku. 2001 Nov;38(6):747-54.
3
Hospital discharge of patients with thyroid carcinoma treated with 131I.接受¹³¹I治疗的甲状腺癌患者出院情况。
J Nucl Med. 2002 Jan;43(1):61-5.
4
Hospital discharge policy in thyroid cancer patients treated with 131I: the effect of changing from fixed time to exposure rate threshold.接受131I治疗的甲状腺癌患者的出院政策:从固定时间改为暴露率阈值的影响。
Health Phys. 1997 Mar;72(3):476-80. doi: 10.1097/00004032-199703000-00017.
5
Criteria for patient release according to external dose rate and residual activity in patients treated with 131I-sodium iodide in Iran.伊朗131碘-碘化钠治疗患者基于外照射剂量率和残余活度的出院标准。
Radiat Prot Dosimetry. 2011 Sep;147(1-2):264-6. doi: 10.1093/rpd/ncr305. Epub 2011 Jul 13.
6
External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.放射性碘治疗良性甲状腺肿的外照射剂量率:估算与直接测量
Scand J Clin Lab Invest. 2006;66(6):509-16. doi: 10.1080/00365510600844663.
7
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.托西莫单抗和(131)I-托西莫单抗治疗后患者出院的实用方法。
J Nucl Med. 2002 Mar;43(3):354-63.
8
A practical guideline for the release of patients treated by I-131 based on Monte Carlo dose calculations for family members.基于对家庭成员的蒙特卡洛剂量计算制定的碘-131治疗患者出院实用指南。
J Radiol Prot. 2014 Jun;34(2):N7-17. doi: 10.1088/0952-4746/34/2/N7. Epub 2014 Apr 4.
9
Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital.接受 131I 治疗的甲状腺癌患者:出院后亲属的辐射剂量。
Thyroid. 2012 Jan;22(1):59-63. doi: 10.1089/thy.2010.0406. Epub 2011 Dec 2.
10
Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy.估算甲状腺切除术后接受放射性碘治疗的患者的医护人员所受外照射剂量。
Health Phys. 2014 Apr;106(4):466-74. doi: 10.1097/HP.0b013e3182a415eb.

引用本文的文献

1
Manual on the proper use of the At-labeled PSMA ligand ([At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition).《靶向 alpha 治疗临床试验中使用放射性标记 PSMA 配体([At]PSMA-5)的操作手册》(第一版)。
Ann Nucl Med. 2024 May;38(5):329-336. doi: 10.1007/s12149-024-01916-6. Epub 2024 Mar 28.
2
Manual on the proper use of meta-[At] astato-benzylguanidine ([At] MABG) injections in clinical trials for targeted alpha therapy (1st edition).用于靶向 α 治疗临床试验中注射用 meta-[At] 间位碘代苄胍(MABG)的正确使用手册(第一版)。
Ann Nucl Med. 2022 Aug;36(8):695-709. doi: 10.1007/s12149-022-01765-1. Epub 2022 Jul 6.
3
Manual on the proper use of sodium astatide ([At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition).
《靶向 alpha 治疗临床试验中锝[At]酸钠注射液正确使用手册》(第一版)。
Ann Nucl Med. 2021 Jul;35(7):753-766. doi: 10.1007/s12149-021-01619-2. Epub 2021 May 12.
4
Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials.钇-90 标记抗 P-钙黏蛋白抗体注射液用于临床试验的放射性核素治疗的正确使用手册。
Ann Nucl Med. 2019 Nov;33(11):787-805. doi: 10.1007/s12149-019-01409-x. Epub 2019 Oct 12.
5
Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.靶向α治疗(使用镭-223)在日本临床实践中的引入:经验与实施
Ann Nucl Med. 2019 Mar;33(3):211-221. doi: 10.1007/s12149-018-1317-1. Epub 2018 Nov 27.
6
Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).镥[177Lu]标记生长抑素类似物(Lu-177-DOTA-TATE)注射液在放射性核素治疗中的正确使用手册(第 2 版)。
Ann Nucl Med. 2018 Apr;32(3):217-235. doi: 10.1007/s12149-018-1230-7. Epub 2018 Jan 15.